Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases. Their lead candidate, ATH434, aims to inhibit the aggregation of pathological proteins involved in neurodegeneration, with potential applications in Parkinson’s disease and related disorders. The company operates in Melbourne, Australia, and San Francisco, USA, and has a history dating back to 1997. They focus on innovative drug discovery and have ongoing clinical trials, including Phase 2 studies for Multiple System Atrophy (MSA). Their mission is to create an alternate, healthier future for people with neurodegenerative diseases by targeting underlying pathology and potentially changing disease progression.
Industries
Nr. of Employees
small (1-50)
Alterity Therapeutics
Suite 4, Level 14, 350 Collins Street, Melbourne VIC 3000 Australia
Patents
Products
ATH434 (oral small-molecule candidate)
Oral, brain-penetrant small-molecule candidate designed to reduce pathological protein aggregation in the central nervous system through moderate affinity interaction with loosely bound iron; advanced to human Phase 1 and Phase 2 clinical studies.
ATH434 (oral small-molecule candidate)
Oral, brain-penetrant small-molecule candidate designed to reduce pathological protein aggregation in the central nervous system through moderate affinity interaction with loosely bound iron; advanced to human Phase 1 and Phase 2 clinical studies.
Services
Design and conduct of clinical trials (randomized, double-blind, placebo-controlled and open-label biomarker studies) including safety, pharmacokinetics, biomarker and imaging assessments.
Discovery and optimization of patentable small-molecule chemical scaffolds using SAR insights to generate candidates for neurodegenerative disease indications.
Execution of natural history cohort studies to characterize disease progression and identify biomarkers suitable for clinical trials.
Design and conduct of clinical trials (randomized, double-blind, placebo-controlled and open-label biomarker studies) including safety, pharmacokinetics, biomarker and imaging assessments.
Discovery and optimization of patentable small-molecule chemical scaffolds using SAR insights to generate candidates for neurodegenerative disease indications.
Execution of natural history cohort studies to characterize disease progression and identify biomarkers suitable for clinical trials.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Biomarker development and validation
- Neurodegenerative disease research
- Small-molecule drug discovery and medicinal chemistry
Key Technologies
- Small-molecule therapeutics
- Iron-targeting small molecules (iron chaperone approach)
- Alpha-synuclein aggregation inhibition
- MRI-based neuroimaging
News & Updates
Published scientific research at the 2025 International MSA Congress.
Research presented at the 2025 International MSA Congress.
Research presented at the 2025 International MSA Congress.
Published scientific research at the 2025 International MSA Congress.
Research presented at the 2025 International MSA Congress.
Research presented at the 2025 International MSA Congress.